Vivo Capital, LLC Zymeworks Inc. Transaction History

Vivo Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $13.9 Million - $19.5 Million	-354,347 Reduced 55.33%	286,064 $13.5 Million
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $2.74 Million - $4.37 Million	-93,750 Reduced 12.77%	640,411 $29.8 Million
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $12.4 Million - $14.7 Million	-367,075 Reduced 33.33%	734,161 $26.5 Million
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $26.7 Million - $54.8 Million	1,101,236 New	1,101,236 $39.1 Million
Q3 2019 Nov 13, 2019	SELL	$22.78 - $29.08 $33.1 Million - $42.3 Million	-1,453,467 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$15.0 - $22.49 $12.5 Million - $18.7 Million	833,333 Added 134.38%	1,453,467 $32 Million
Q2 2018 Aug 10, 2018	BUY	$11.13 - $21.86 $6.9 Million - $13.6 Million	620,134 New	620,134 $9.17 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.